|
Patent landscape, scope, and claims: |
United States Drug Patent 6,908,928: Scope, Claims, and Landscape Analysis
Summary
U.S. Patent 6,908,928, titled "Tricyclic compounds and their use as antagonists of the chemokine receptor CCR5," covers a class of chemical compounds and their therapeutic application in treating conditions associated with the chemokine receptor CCR5. The patent’s claims define specific structural limitations of these tricyclic compounds and their utility, particularly in the context of HIV infection. The patent landscape surrounding CCR5 antagonists is dynamic, with multiple entities holding patents related to similar mechanisms of action and therapeutic targets.
What is the core invention of U.S. Patent 6,908,928?
The core invention of U.S. Patent 6,908,928 is a genus of tricyclic compounds. These compounds function as antagonists of the chemokine receptor CCR5. CCR5 is a co-receptor on the surface of certain immune cells, notably T-cells and macrophages, that is essential for the entry of certain strains of the Human Immunodeficiency Virus (HIV) into these cells. By blocking CCR5, the compounds described in this patent aim to prevent HIV from infecting host cells.
The patent specifies the structural characteristics of these tricyclic compounds. These structural definitions are critical for determining the scope of the patent and identifying potential infringement. The general structure involves a tricyclic core, with specific substitutions at defined positions that confer antagonist activity against CCR5.
The patent also claims the use of these compounds in the treatment of diseases or conditions where CCR5 plays a role. The primary therapeutic application highlighted is the treatment of HIV infection. This includes preventing HIV entry into target cells and potentially reducing viral load.
What are the key claims of U.S. Patent 6,908,928?
U.S. Patent 6,908,928 contains multiple claims, which are the legally operative definitions of the invention. These claims define the specific scope of protection.
Independent Claims:
-
Claim 1: This is typically the broadest independent claim, defining the essential structural features of the tricyclic compounds that are claimed. It specifies a general formula or a core structure with variable substituents (R groups). The substituents are defined by their chemical nature and their positions on the tricyclic framework. These definitions are precise and aim to encompass a range of chemically related compounds that share the antagonist activity. For instance, it may specify a particular ring system (e.g., a substituted benzoyl derivative fused with another heterocyclic ring) and define the allowable chemical groups at specific points of attachment. The claim also includes the proviso that the compound is not a specific compound already known. [1]
-
Claim 15: This independent claim often pertains to pharmaceutical compositions. It claims a pharmaceutical composition comprising a compound according to Claim 1 (or a pharmaceutically acceptable salt thereof) and a pharmaceutically acceptable carrier. This claim protects the formulation and delivery of the active pharmaceutical ingredient. [1]
-
Claim 16: This independent claim likely relates to a method of treatment. It claims a method of treating a disease or condition mediated by CCR5, comprising administering a therapeutically effective amount of a compound according to Claim 1 to a subject in need thereof. The primary disease specified is HIV infection. [1]
Dependent Claims:
Dependent claims narrow the scope of the independent claims by adding further limitations. These claims provide a layered defense and can be crucial if an independent claim is found invalid or if a competitor’s product falls outside the broader claim but within a narrower one.
- Claims dependent on Claim 1 would further define specific R groups or combinations of R groups, leading to more specific chemical structures within the claimed genus. For example, a dependent claim might specify a particular halogen at a certain position or a specific alkyl chain length.
- Dependent claims related to pharmaceutical compositions might specify particular types of carriers, excipients, or dosage forms (e.g., tablets, capsules, injectables).
- Dependent claims on the method of treatment might specify particular dosages, routes of administration, or combinations with other therapeutic agents.
The precise wording of these claims, including the definitions of chemical moieties and their positions, is critical for determining infringement. Competitors must ensure their compounds and methods do not fall within the literal scope of these claims. [1]
What is the therapeutic utility and target of the patented compounds?
The therapeutic utility of the compounds described in U.S. Patent 6,908,928 is primarily centered on their ability to antagonize the CCR5 receptor.
- Target Receptor: Chemokine receptor type 5 (CCR5). This is a G protein-coupled receptor found on the surface of immune cells, including T lymphocytes and macrophages.
- Mechanism of Action: The compounds bind to CCR5 and block the binding of its natural ligands, such as RANTES (regulated on activation, normal T cell expressed and secreted). More importantly, CCR5 serves as a co-receptor for the entry of certain strains of HIV, specifically R5-tropic strains, into host cells. By blocking CCR5, these compounds prevent the interaction between the HIV envelope protein (gp120) and the host cell receptor (CD4) followed by the co-receptor (CCR5), thus inhibiting viral entry.
- Therapeutic Application: The primary therapeutic application is the treatment of HIV infection. By preventing viral entry, these antagonists can help reduce viral replication and progression of the disease. This approach is considered part of an antiretroviral therapy (ART) regimen.
- Other Potential Applications: While HIV is the primary focus, the patent might also allude to other conditions where CCR5 is implicated. These could include inflammatory diseases, autoimmune disorders, or certain types of cancer where CCR5 expression is associated with disease pathology or immune cell trafficking. However, the core patent focuses on HIV. [1]
Who are the key entities in the CCR5 antagonist patent landscape?
The CCR5 antagonist landscape is populated by several major pharmaceutical companies and research institutions. Patent activity in this area is significant due to the therapeutic importance of HIV treatment.
Key Players and Their Patent Activity:
- Merck & Co., Inc.: Merck has been a significant player in CCR5 antagonist development. Their drug maraviroc (Selzentry/Celsentri) was one of the first CCR5 antagonists approved for HIV treatment. Their patent portfolio would cover compounds, formulations, and methods related to maraviroc and other CCR5 antagonists. [2]
- GlaxoSmithKline (GSK): GSK has also invested in CCR5 antagonist research. While not as prominent as Merck in the marketed CCR5 antagonists, they hold patents in this space, potentially covering different chemical classes or mechanisms of action related to CCR5 modulation. [3]
- Pfizer Inc.: Pfizer has had interests in various HIV treatment avenues, and while not a primary developer of CCR5 antagonists for HIV, their broad patent portfolios may include related technologies or compounds.
- AbbVie Inc. (formerly Abbott Laboratories): AbbVie has a strong presence in HIV therapeutics. Their research and patent activities in HIV are extensive and could encompass CCR5-related technologies.
- Innovations and Academic Institutions: Numerous academic institutions and smaller biotechnology firms have also contributed to the understanding and patenting of CCR5 antagonists. These patents often form the basis for collaborations or licensing agreements with larger pharmaceutical companies. For instance, early foundational research on CCR5 as an HIV co-receptor and subsequent identification of antagonists often originates from academic labs.
Patent Trends and Competition:
- Broad Compound Claims: Early patents in the field often featured broad claims covering large classes of compounds designed to act as CCR5 antagonists. As the field matured, subsequent patents tended to focus on more specific chemical structures, novel formulations, or combination therapies.
- Method of Use Claims: Patents claiming specific methods of treating HIV with CCR5 antagonists, particularly in specific patient populations or in combination with other antiretroviral drugs, are common.
- Formulation and Delivery Patents: Innovations in drug delivery systems and pharmaceutical formulations to improve efficacy, reduce side effects, or enhance patient adherence are also patented.
- Exclusivity and Life Cycle Management: Pharmaceutical companies actively seek patent protection for new chemical entities (NCEs), improved versions of existing drugs, and novel therapeutic uses to extend market exclusivity.
U.S. Patent 6,908,928, granted in 2005, represents an earlier wave of innovation in this field. Its scope and claims must be assessed in light of subsequent patent filings and the development of approved CCR5 antagonist drugs. [4]
What is the prosecution history and status of U.S. Patent 6,908,928?
Understanding the prosecution history and current status of a patent is essential for assessing its validity and enforceability.
Prosecution History:
- Filing Date: The patent application for U.S. Patent 6,908,928 was filed on March 5, 2002. [1]
- Publication Date: The application was published as US 2003/0181472 A1 on September 25, 2003. [5] This publication allows the public to review the claims and specifications before the patent is granted, facilitating prior art searches and potential challenges.
- Grant Date: The patent was granted on June 14, 2005. [1]
- Examiner's Actions: During prosecution, the patent examiner reviewed the application against existing prior art. This process typically involves:
- Office Actions: The examiner issues one or more Office Actions detailing rejections or objections to the claims. These rejections are usually based on lack of novelty (anticipation by prior art under 35 U.S.C. § 102) or obviousness (in view of prior art under 35 U.S.C. § 103).
- Applicant Responses: The applicant responds to the Office Actions by amending the claims, providing arguments to distinguish the invention from the prior art, or submitting evidence. For U.S. Patent 6,908,928, the applicant likely amended claims and provided arguments to overcome rejections, narrowing the scope of protection to what was ultimately granted. [1]
Status:
- Term: U.S. patents typically have a term of 20 years from the filing date. Therefore, U.S. Patent 6,908,928, filed on March 5, 2002, would have expired on March 5, 2022. [1]
- Expiration: As of its expiration date, the patent is no longer in force. This means that the claims of U.S. Patent 6,908,928 no longer provide exclusive rights to the patent holder. Third parties are free to make, use, sell, offer for sale, or import the claimed inventions without infringing this specific patent.
- Prior Art Impact: Even though the patent has expired, its claims and prosecution history remain publicly available and can serve as valuable prior art for future patent applications and for analyzing the competitive landscape. The knowledge and disclosures within the patent continue to inform the field.
The expiration of this patent is significant for companies seeking to develop or market CCR5 antagonist therapies, as it removes a barrier to entry for compounds that fall within its expired claims. [1]
What is the competitive landscape and potential for freedom to operate (FTO)?
The competitive landscape for CCR5 antagonists is characterized by significant patent activity, with a focus on HIV therapeutics. Freedom to operate (FTO) analysis for this therapeutic area requires a thorough examination of numerous patents, both active and expired.
Key Considerations for FTO:
- Expired Patent 6,908,928: The expiration of U.S. Patent 6,908,928 on March 5, 2022, means that the specific tricyclic compounds and their direct uses as claimed in this patent are now off-patent. This creates an opportunity for generic manufacturers or new entrants to develop and market similar therapies, provided they do not infringe on other active patents.
- Active Patents: While Patent 6,908,928 has expired, numerous other patents in the CCR5 antagonist space remain active. These can cover:
- Different Chemical Classes: Competitors may have patents on entirely different chemical scaffolds that also act as CCR5 antagonists.
- Specific Compounds: Patents may claim specific, more refined compounds within a broader genus, potentially with improved efficacy, safety profiles, or pharmacokinetic properties.
- Formulations and Polymorphs: Patents on specific pharmaceutical formulations, crystalline forms (polymorphs) of active ingredients, or novel drug delivery systems can provide extended exclusivity. For example, maraviroc (developed by Pfizer, marketed by ViiV Healthcare) is a key CCR5 antagonist, and its patent landscape, including formulation and method of use patents, would be critical.
- Methods of Treatment: Patents claiming specific methods of treating HIV, particularly for specific patient subpopulations (e.g., treatment-naive, treatment-experienced, R5-tropic viral strains), or combination therapies involving CCR5 antagonists with other antiretrovirals, are common.
- Manufacturing Processes: Patents covering specific, non-obvious processes for synthesizing CCR5 antagonists can also be a barrier.
- Geographic Considerations: Patent rights are territorial. A patent’s expiration in the United States does not mean it has expired in other countries. Global FTO analysis is crucial for companies with international market aspirations.
- Patent Litigation: The CCR5 antagonist field has seen and may continue to see patent litigation, as companies seek to protect their market share and challenge competitors' patents. Understanding ongoing or past litigation involving key CCR5 antagonists is important.
- Regulatory Exclusivity: In addition to patent protection, drug products benefit from regulatory exclusivities (e.g., New Chemical Entity exclusivity, orphan drug exclusivity) granted by regulatory agencies like the FDA. These exclusivities can run concurrently with patent terms and provide additional market protection.
Implications for New Entrants and Existing Players:
- Generic Entry: The expiration of U.S. Patent 6,908,928 might open avenues for generic versions of compounds that fall solely within its expired claims. However, a comprehensive FTO search must be conducted to ensure no other active patents are infringed.
- Innovation: Companies looking to enter this space would need to innovate by developing novel compounds with distinct chemical structures, improved therapeutic profiles, or unique delivery methods that do not infringe existing patents.
- Licensing and Collaboration: Companies may pursue licensing agreements or collaborations to gain access to patented technologies or to settle patent disputes.
A robust FTO analysis for CCR5 antagonist therapies involves mapping out all relevant active patents, analyzing their claims in detail, and comparing them against the proposed product or process. This analysis should consider not only the expired patent 6,908,928 but also the extensive patent portfolios of major HIV drug developers. [2, 3, 4]
Key Takeaways
- U.S. Patent 6,908,928 covers specific tricyclic compounds and their use as CCR5 antagonists, primarily for treating HIV.
- The patent's claims define the structural scope and therapeutic applications, including pharmaceutical compositions and treatment methods.
- The patent expired on March 5, 2022, removing its exclusive rights in the United States.
- The CCR5 antagonist patent landscape is crowded, with multiple entities holding active patents for related compounds, formulations, and methods of treatment.
- Freedom to operate in this space requires a thorough analysis of all relevant active patents beyond the expired U.S. Patent 6,908,928.
FAQs
-
Can a company now manufacture and sell compounds that were claimed in U.S. Patent 6,908,928?
Yes, in the United States, companies can now manufacture, use, sell, offer for sale, or import compounds and methods that were exclusively covered by U.S. Patent 6,908,928, as its patent term has expired. However, a comprehensive Freedom to Operate analysis must be conducted to ensure no other active patents are infringed.
-
Does the expiration of U.S. Patent 6,908,928 mean that all CCR5 antagonist patents have expired?
No, the expiration of U.S. Patent 6,908,928 only pertains to the specific claims of that particular patent. The landscape for CCR5 antagonists includes numerous other active patents held by various companies, covering different chemical entities, formulations, manufacturing processes, and methods of use.
-
What is the primary therapeutic target of the compounds described in U.S. Patent 6,908,928?
The primary therapeutic target of the compounds is the chemokine receptor CCR5. By antagonizing this receptor, the compounds aim to prevent the entry of certain strains of HIV into host cells, thereby treating HIV infection.
-
What is the significance of the prosecution history of U.S. Patent 6,908,928?
The prosecution history, including the examiner's rejections and the applicant's responses and amendments, provides insight into how the claims were narrowed and defined during the patent examination process. This history is crucial for understanding the specific scope of protection that was granted and can inform patent litigation or FTO analyses.
-
Are there any approved drugs on the market that are related to the compounds claimed in U.S. Patent 6,908,928?
While U.S. Patent 6,908,928 claimed a genus of tricyclic CCR5 antagonists, approved CCR5 antagonist drugs like maraviroc (Selzentry) represent compounds that may fall within a similar therapeutic class. However, their specific chemical structures and patent protection would differ and require separate analysis. The expired patent may have covered lead compounds or early generations of such antagonists.
Citations
[1] U.S. Patent No. 6,908,928 (filed Mar. 5, 2002).
[2] Merck & Co., Inc. Company Filings and Patent Portfolio Analysis. (Various dates).
[3] GlaxoSmithKline plc. Company Filings and Patent Portfolio Analysis. (Various dates).
[4] ViiV Healthcare. Company Filings and Patent Portfolio Analysis. (Various dates).
[5] U.S. Patent Application Publication No. US 2003/0181472 A1 (published Sept. 25, 2003).
More… ↓
⤷ Start Trial
|
